Croissy-Beaubourg and Montpellier, January 6, 2015 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in theranostics and in vitro diagnostics, announces today its financial reporting schedule for 2015.
Financial publications will be released after market close. This schedule is indicative and subject to change.
- 2014 Full-year sales January 20, 2015
- 2014 Full-year results March 4, 2015
- Annual Shareholders Meeting April 16, 2015
- 2015 First-half results September 16, 2015
About Theradiag
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostics solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.
For further information about Theradiag, please visit our website: www.theradiag.com
| Theradiag |
Investor Relations
Nathalie Trepo
Phone: +33 1 64 62 10 12
NewCap
Financial communications/ Investor relations
Valentine Brouchot /
Pierre Laurent
Phone: +33 1 44 71 94 94
Alize RP
Press
Caroline Carmagnol /
Valentine Boivin
Phone: +33 6 64 18 99 59